You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

To UNSUBSCRIBE from this list, to change your e-mail address, or to subscribe, please go to http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1

Please do not reply to this message.
_______________________________________________

This week marks the tenth anniversary of the approval of the first protease inhibitor.  In December of 1995, a then new class of drug for the treatment of HIV/AIDS in combination with other antiretroviral drugs represented an historic landmark in the treatment of HIV/AIDS.  Protease inhibitors helped establish a new treatment standard of triple combination therapy, significantly improving the lives and health of people living with HIV in the United States and around the world. 

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html